Louis Garguilo
ARTICLES BY LOUIS
-
![Are You The Future of Pharmaceutical Development?]( "Are You The Future of Pharmaceutical Development?")
12/27/2016Pfizer's Bernie Huyghe and ADC Therapeutics' Michael Mulkerrin get bushwhacked with this question in a public forum. Their open replies will help each one of you to your own personal assessment. Be prepared for some soul searching.
-
![Outsourcing 2017: Countries, Costs, And Some Concerns]( "Outsourcing 2017: Countries, Costs, And Some Concerns")
12/19/2016"Topic one for me during 2016 was the rather sudden realization that CMOs will not be able to carry us forward in the near term …” says Darren Dasburg, VP BioVentures – Biologics, Medimmune/AstraZeneca. He and other Outsourced Pharma Editorial Board members provide useful insight for the New Year.
-
![Drug Development In 2017: The Year Of The Middle Way]( "Drug Development In 2017: The Year Of The Middle Way")
12/13/2016I asked members of our Outsourced Pharma Editorial Board for their thoughts on the out-going and in-coming years. We start here with Takuya Seko, Corporate Officer, Executive Director, CMC-Production & CMC Research, Ono Pharmaceutical Co., Ltd., and Piet Houwen, Head of Biologics - External Manufacturing, Sanofi Genzyme.
-
![Thomas Jefferson Hasn’t A Clue About Drug Development]( "Thomas Jefferson Hasn't A Clue About Drug Development")
12/8/2016Understanding what went before, and the steadfast resolve to get to the future, are invaluable for reaching success in our industry. An illustrative and teaching example of this – including the past and future of outsourcing – is embodied in the people at a “thirty-year-old biotech.” They have little in common with Thomas Jefferson.
-
![Are CMOs Sufficiently Serving Biotechs?]( "Are CMOs Sufficiently Serving Biotechs?")
11/29/2016Louis Demers of Xoma knows what he wants in contract development and manufacturing organizations. For example, they should be networked with other service providers, and in mission-critical alignment. Can he get what he wants? Can any outsourcing leader at a biotech today? CMO consolidation may make it more difficult.
-
![Is Pharma’s New HR “Majority” Good For Hiring?]( "Is Pharma's New HR “Majority” Good For Hiring?")
11/16/2016What impact is a growing class of front-line hiring professionals in the human resources departments of the biotechnology, pharmaceutical, and contract services industries having on the employment of drug development outsourcing professionals? Is this a part of a societal shift?
-
![Pharma Copycats In CMO Acquisition Strategy]( "Pharma Copycats In CMO Acquisition Strategy")
11/11/2016It used to be Pharma swept up emerging companies and their new technologies. Now CMOs do so as well. With Pharma, the technologies might end up on the shelf; not so with CMOs. But what about those emerging companies themselves? "If there are two guys thinking about doing a startup, they should do it,” we’re told.
-
![Pharma’s Potemkin Village On The River Of Outsourcing]( "Pharma's Potemkin Village On The River Of Outsourcing")
11/9/2016Grigory Potemkin was governor of war-ravaged New Russia in 1787. He’s said to have deployed a shiny “mobile village” along the Dnieper River to impress Catherine II (and the world) as she inspected the region from her barge. Were we, too, in the year 2016, deploying polished porticoes to hide a dimmer reality, at our Outsourced Pharma conferences?
-
![Pfizer Sets Example For CMOs In M&A Strategy]( "Pfizer Sets Example For CMOs In M&A Strategy")
10/24/2016“Big CMOs” acquire smaller contract development and manufacturing organizations in the same way as Big Pharma has historically acquired biotechs and smaller drug developers. This allegory resurfaced with Pfizer’s recent asset acquisition of Bind Therapeutics. What better modern-day model for CMOs to emulate? And we’ve just seen the cases of Catalent’s gobbling up Pharmatek, and Piramal lassoing Ash Stevens …
-
![Tech Transfer: Documents Needing People]( "Tech Transfer: Documents Needing People")
10/11/2016"Documents transfer information; people transfer knowledge.” Too prosaic for your tastes? Perhaps. But there’s little debate regarding the applicability of this axiom to drug development and manufacturing. It's espoused by industry veterans with experience transferring projects from one organization to another, and even by younger professionals who’ve grown up communicating virtually.
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.